Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia by Carlos Jiménez-Vicente, Iago Arribas, Helena Pomares, Guillermo Ramil, Sandra Castaño-Diez, Amanda Isabel Pérez-Valencia, Antonella Luciana Sturla, Mònica López-Guerra, Alexandra Martinez-Roca, Inés Zugasti, Francesca Guijarro, Albert Cortés-Bullich, Beatriz Merchán, Ana Triguero, Inés Monge, Albert Tuca, Guadalupe Oñate, Ana Garrido, Jorge Sierra, Montserrat Arnan, Jordi Esteve, Marina Díaz-Beyá, Spanish CETLAM Group

Get full text

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study by Ines Zugasti, Monica Lopez-Guerra, Sandra Castaño-Díez, Daniel Esteban, Alejandro Avendaño, Helena Pomares, Ana Perez, Sara García-Ávila, Irene Padilla Conejo, Cristina de la Fuente Montes, Alexandra Martínez-Roca, Beatriz Merchán, Carlos Jiménez-Vicente, Francesca Guijarro, Jose Ramón Álamo, Albert Cortes-Bullich, Victor Torrecillas, Lucia Mont, Esther Carcelero, Gisela Riu, Lurdes Zamora, Joan Bargay, Ana Triguero, Maria Suarez-Lledó, Maria Queralt Salas, Felix López-Cadenas, Fernando Ramos, Blanca Xicoy, David Valcárcel, Montserrat Arnan, Carmen Martínez, Montserrat Rovira, Francesc Fernández-Avilés, Maria Díez-Campelo, Jordi Esteve, Marina Díaz-Beyá

Get full text